[시장보고서]세계의 혈전용해요법 시장 : 약제 유형별, 적응증별, 최종 사용자별, 투여법별, 유통 채널별, 환자 연령별, 포장 유형별, 용도별, 투약형별, 지역별

세계의 혈전용해요법 시장 : 약제 유형별, 적응증별, 최종 사용자별, 투여법별, 유통 채널별, 환자 연령별, 포장 유형별, 용도별, 투약형별, 지역별

Fibrinolytic Therapy Market By Drug Type, By Indication, By End User, By Administration, By Distribution Channel, By Patient Age, By Packaging Type, By Application, By Dosage Form, By Region

상품코드 : 1741153

리서치사 : Coherent Market Insights

발행일 : 2025년 03월

페이지 정보 : 영문

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,513,000

Unprintable PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 7,000

￦ 10,131,000

PDF & Excel (Multi User License - Up to 7 Users)

PDF & Excel 보고서를 동일 기업 최대 7명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능하며, 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

US $ 10,000

￦ 14,474,000

PDF & Excel (Corporate User License)

PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 혈전용해요법 시장은 2025년 375억 9,000만 달러로 추정되며, 2032년까지 484억 8,000만 달러에 이를 것으로 예측되며, 2025년부터 2032년까지 CAGR 3.7%로 성장할 전망입니다.

보고 범위		보고서 세부정보
기준연도	2024년	2025년 시장 규모	375억 9,000만 달러
실적 데이터	2020-2024년	예측 기간	2025-2032년
예측 기간: 2025-2032년 CAGR:	3.70%	2032년 가치 예측	484억 8,000만 달러

혈전용해요법은 심장 발작이나 뇌졸중의 원인이 되는 혈전을 용해하기 위해 사용됩니다. 집이나 병원에서 투여할 수 있습니다.

시장 역학

외상이나 교통사고 증가에 의해 항선용약 수요가 높아지고 있어 그것이 혈전용해요법 시장의 성장을 뒷받침하고 있습니다. 심각한 교통사고나 외상의 발생건수 증가가 항선용약 수요를 낳고 시장 성장을 뒷받침하고 있습니다. 게다가 혈우병이나 혈소판 기능부전, 폰빌레브란트병, 혈우병 A 및 B 등의 다른 질환의 치료에 이러한 약제의 채용이 증가하고 있는 것도 시장의 성장을 더욱 뒷받침하고 있습니다.

또한 세계 혈전용해요법 시장은 혈전의 원인이 되는 심혈관질환, 신경질환, 폐질환의 유병률 상승에 의해 견인되고 있습니다. 그러나 약의 높은 가격, 엄격한 규제, 치료에 따른 출혈의 위험이 시장 확대를 저해하고 있습니다.

이러한 약물의 높은 가격은 시장 성장을 방해하는 중요한 요소입니다.

본 조사의 주요 특징

본 보고서에서는 세계 혈전용해요법 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간(2025-2032년) 중 시장 규모 및 CAGR을 제공합니다.
또, 다양한 부문에 걸친 잠재적인 수익 기회를 밝혀, 이 시장의 매력적인 투자 제안 매트릭스에 대해서 해설했습니다.
또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 상시나 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 성과, 전략 등의 매개변수를 기반으로 세계 혈전용해요법 시장의 주요 기업 프로파일을 제공합니다.
이 보고서의 통찰을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전술에 대한 정보를 바탕으로 의사 결정을 내릴 수 있습니다.
세계 혈전용해요법 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자를 지원합니다.
이해관계자들은 세계 혈전용해요법 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.

시장 역학
- 드라이버
심혈관 질환의 발생률 증가
고령화 인구 증가
기술의 진보
의료시설에의 액세스
- 억제요인
특정 환자 집단에서는 효과가 한정되어 있다
출혈성 합병증의 위험
대체 치료법의 이용 가능성
시간에 대한 민감성과 투여까지의 지연
- 기회
신흥 시장
병용 요법
원격 의료 및 원격 치료
맞춤형 의료
- 주요 하이라이트
- 규제 시나리오
- 최근 동향
- 제품 출시/승인
- PEST 분석
- PORTER 분석
- 합병, 인수 및 제휴

제4장 세계의 혈전용해요법 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

COVID-19 역학
공급측과 수요측의 분석
경제에 미치는 영향

제5장 세계의 혈전용해요법 시장 : 약제 유형별, 2020-2032년

알테프라제
레테프라제
테낙테프라제
스트렙토키나아제
아니스트레프라제
우로키나제

제6장 세계의 혈전용해요법 시장 : 적응증별, 2020-2032년

급성 허혈성 뇌졸중
급성 심근경색
심부정맥혈전증
말초동맥혈전증
기타 동맥혈전증

제7장 세계의 혈전용해요법 시장 : 최종 사용자별, 2020-2032년

병원
외래수술센터(ASC)
전문 클리닉
기타

제8장 세계의 혈전용해요법 시장 : 관리 분야별, 2020-2032년

정맥내(IV)
동맥내(IA)

제9장 세계의 혈전용해요법 시장 : 유통 채널별, 2020-2032년

병원 약국
소매 약국
온라인 약국

제10장 세계의 혈전용해요법 시장 : 환자 연령별, 2020-2032년

성인 환자
소아 환자

제11장 세계의 혈전용해요법 시장 : 포장 유형별, 2020-2032년

바이알
앰풀
프리필드 주사기

제12장 세계의 혈전용해요법 시장 : 용도별, 2020-2032년

응급의료
인터벤셔널 카디올로지
혈전증 치료
기타

제13장 세계의 혈전용해요법 시장 : 제형별, 2020-2032년

재용해용 동결건조 분말
주사액

제14장 세계의 혈전용해요법 시장 : 지역별, 2020-2032년

북미
유럽
아시아태평양
라틴아메리카
중동
아프리카

제15장 경쟁 구도

기업 프로파일
- Genentech, Inc.(Roche)
- Bayer AG
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Bristol Myers Squibb Company
- Novarts AG
- AstraZeneca PLC
- Johnson & Johnson
- Daiichi Sankyo Company, Limited
- Merck & Co., Inc.
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Abbott Laboratories
- Mallinckrodt Pharmaceuticals
- Mitsubishi Tanabe Pharma Corporation

제16장 섹션

참고문헌
조사 방법
출판사에 대해

JHS

영문 목차

영문목차

Fibrinolytic Therapy Market is estimated to be valued at USD 37.59 Bn in 2025 and is expected to reach USD 48.48 Bn by 2032, growing at a compound annual growth rate (CAGR) of 3.7% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 37.59 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	3.70%	2032 Value Projection:	USD 48.48 Bn

Fibrinolytic therapy is used to dissolve blood clots that cause heart attacks or strokes. It is a lifesaving treatment, but it fails in underlying health problems that can lead to other serious diseases and conditions. Thrombolysis is usually given through an intravenous line. It is used when symptoms of a stroke or heart attack are present and the patient is not responding to other treatments, like anticoagulants and steroid medications. It can be given at home or in a hospital. Tissue plasminogen activator or alteplase is a drug that breaks down fibrin and other substances that create clots in the body that is most commonly used for thrombolysis. The drug tenecteplase is also effective in some patients, and it can also be given by mouth.

Market Dynamic:

The increasing incidences of trauma and road accidents are driving the demand for antifibrinolytic drugs, which in turn is fuelling fibrinolytic therapy market growth. The growing use of these drugs in oral bleeding treatments, mainly for menorrhagia (heavy menstrual flow) is again anticipated to bolster the market growth further. Moreover, rising incidences of severe road accidents and trauma is creating demand for anti-fibrinolytic drugs, thereby propelling the market growth. Furthermore, rising adoption of these drugs for treating hemophilia and other conditions such as platelet dysfunctions, Von Willebrand diseases and haemophilia A and B is further bolstering the market growth.

Also, the global fibrinolytic therapy market is driven by the rising prevalence of cardiovascular diseases, neurological disorders and pulmonary diseases causing blood clots. As per World Health Organization (WHO), cardiovascular diseases accounts for over 17.9 Mn deaths annually. Moreover, growing geriatric population prone to such diseases contributes to the market growth. However, high costs of fibrinolytic drugs, stringent regulations, and risk of bleeding associated with the therapy inhibits the market expansion. The market provides opportunities for development of effective recombinant variants, synthetic analogs, and hybrid molecules with greater specificity, enhanced fibrin specificity and reduced bleeding risks.

However, the high price of these drugs is a key factor that can hinder the market growth.

Key features of the study:

This report provides in-depth analysis of the global fibrinolytic therapy market, and provides market size (US$ Bn ) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global fibrinolytic therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Genentech, Inc. (Roche), Bayer AG, Boehringer Ingelheim International GmbH, Pfizer Inc., Bristol Myers Squibb Company, Novartis AG, AstraZeneca PLC, Johnson & Johnson, Daiichi Sankyo Company, Limited, Merck & Co., Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Abbott Laboratories, Mallinckrodt Pharmaceuticals, and Mitsubishi Tanabe Pharma Corporation
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global fibrinolytic therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fibrinolytic therapy market

Detailed Segmentation:

Global Fibrinolytic Therapy Market, By Drug Type:
- Alteplase
- Reteplase
- Tenecteplase
- Streptokinase
- Anistreplase
- Urokinase
Global Fibrinolytic Therapy Market, By Indication:
- Acute Ischemic Stroke
- Acute Myocardial Infarction
- Deep Vein Thrombosis
- Peripheral Arterial Thrombosis
- Other Arterial Thrombosis
Global Fibrinolytic Therapy Market, By End User:
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
- Others
Global Fibrinolytic Therapy Market, By Administration:
- Intravenous (IV)
- Intra-arterial (IA)
Global Fibrinolytic Therapy Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Fibrinolytic Therapy Market, By Patient Age:
- Adult Patients
- Pediatric Patients
Global Fibrinolytic Therapy Market, By Packaging Type:
- Vials
- Ampoules
- Pre-filled Syringes
Global Fibrinolytic Therapy Market, By Application:
- Emergency Care
- Interventional Cardiology
- Thrombosis Treatment
- Others
Global Fibrinolytic Therapy Market, By Dosage Form:
- Lyophilized Powder for Reconstitution
- Solution for Injection
Global Fibrinolytic Therapy Market, By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles
- Genentech, Inc. (Roche)
- Bayer AG
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Bristol Myers Squibb Company
- Novartis AG
- AstraZeneca PLC
- Johnson & Johnson
- Daiichi Sankyo Company, Limited
- Merck & Co., Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Abbott Laboratories
- Mallinckrodt Pharmaceuticals
- Mitsubishi Tanabe Pharma Corporation

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Indication
- Market Snippet, By End User
- Market Snippet, By Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Patient Age
- Market Snippet, By Packaging Type
- Market Snippet, By Application
- Market Snippet, By Dosage Form
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Driver
Increasing incidence of cardiovascular diseases
Growing geriatric population
Technological advancements
Access to healthcare facilities
- Restrain
Limited efficacy in certain patient populations
Risk of bleeding complications
Availability of alternative treatment modalities
Time sensitivity and door-to-needle delays
- Opportunities
Emerging markets
Combination therapies
Telemedicine and remote treatment
Personalized medicine
- Key Highlights
- Regulatory Scenario
- Recent Trends
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Mergers, Acquisitions, and Collaborations

4. Global Fibrinolytic Therapy Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Fibrinolytic Therapy Market, By Drug Type, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2020 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Alteplase
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Reteplase
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Tenacteplase
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Streptokinase
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Anistreplase
- Introduction
- Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Urokinase
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Fibrinolytic Therapy Market, By Indication, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2020 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Acute Ischemic Stroke
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Acute Myocardial Infarction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Deep Vein Thrombosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Peripheral Arterial Thrombosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Other Arterial Thrombosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,US$ Bn(US$ Bn)

7. Global Fibrinolytic Therapy Market, By End User, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2020 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Speciality Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Global Fibrinolytic Therapy Market, By Administration, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2020 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Intravenous (IV)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Intra-arterial (IA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

9. Global Fibrinolytic Therapy Market, By Distribution Channel, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2020 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

10. Global Fibrinolytic Therapy Market, By Patient Age, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2020 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Adult Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Pediatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

11. Global Fibrinolytic Therapy Market, By Packaging Types, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2020 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Vials
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Ampoules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Pre-filled Syringes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

12. Global Fibrinolytic Therapy Market, By Application, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2020 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Emergency Care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Interventional Cardiology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Thrombosis Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

13. Global Fibrinolytic Therapy Market, By Dosage Form, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2020 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Lyophilized Powder for Reconstitution
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Solution for Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

14. Global Fibrinolytic Therapy Market, By Region, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, By Region, 2020 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 -2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Bn)
  - South Africa
  - Central Africa
  - North Africa

15. Competitive Landscape

Company Profile
- Genentech, Inc. (Roche)
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
- Bayer AG
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Boehringer Ingelheim International GmbH
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Pfizer Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Bristol Myers Squibb Company
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Novarts AG
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- AstraZeneca PLC
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Johnson & Johnson
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Daiichi Sankyo Company, Limited
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Merck & Co., Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Sanofi S.A.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Takeda Pharmaceutical Company Limited
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Abbott Laboratories
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Mallinckrodt Pharmaceuticals
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Mitsubishi Tanabe Pharma Corporation
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Analyst Views

16. Section

References
Research Methodology
About us